Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
From the updated Bethesda Declaration and controversy at the American Diabetes Association annual meeting, to high-stakes negotiations on the UN Political Declaration on HIV/AIDS ahead of the upcoming High-Level Meeting, the politicization of science and public health are on full display this week.
Blog Post
As scientific progress accelerates, AVAC’s cure programs are ensuring communities remain at the center of the agenda. Through initiatives like the US HIV Cure Academy, global advocacy convenings and community-led storytelling, AVAC is equipping advocates with the knowledge and networks needed to shape the future of HIV cure research and bridge the gap between complex science and the communities most impacted by HIV.
Blog Post
In April 2026, AVAC, the Well Project and the Martin Delaney Collaboratories brought together skilled advocates together, along with leading researchers and cure experts, for the US HIV Cure Academy. The Academy is designed to strengthen understanding of HIV cure science and build research translation skills in support of advocacy efforts. Learn more.
showing 1-10 of 1231
From the updated Bethesda Declaration and controversy at the American Diabetes Association annual meeting, to high-stakes negotiations on the UN Political Declaration on HIV/AIDS ahead of the upcoming High-Level Meeting, the politicization of science and public health are on full display this week.
As scientific progress accelerates, AVAC’s cure programs are ensuring communities remain at the center of the agenda. Through initiatives like the US HIV Cure Academy, global advocacy convenings and community-led storytelling, AVAC is equipping advocates with the knowledge and networks needed to shape the future of HIV cure research and bridge the gap between complex science and the communities most impacted by HIV.
In April 2026, AVAC, the Well Project and the Martin Delaney Collaboratories brought together skilled advocates together, along with leading researchers and cure experts, for the US HIV Cure Academy. The Academy is designed to strengthen understanding of HIV cure science and build research translation skills in support of advocacy efforts. Learn more.
Prevention Option:
A new proposed White House OMB rule seeking greater political oversight of federal grantmaking puts research in peril; vaccine developments accelerate as the Ebola Bundibugyo outbreak grows; the US Secretary of State takes questions from multiple Congressional committees about the future of PEPFAR; responding to the Ebola outbreak; support of Gavi, the Vaccine Alliance; and US global health security.
In a landmark moment, South Africa today became the 9th African country to introduce lencapavir (LEN) for HIV prevention. South Africa’s introduction of LEN is especially significant given the country’s central role in shaping the regional HIV response and the global PrEP market. As the largest PrEP market in the world, South Africa’s leadership can help drive the demand, volume, market confidence and lower prices needed to accelerate equitable access across the continent and the world.
Prevention Option:
In an ongoing attempt to decimate and politicize science, the White House Office of Management and Budget proposed sweeping new regulations to significantly expand political interference in federal research funding decisions across all federal grants, threatening science, global health and the HIV/AIDS response.
Injectable lenacapavir for PrEP (LEN) is rolling out across Africa faster than any HIV prevention option to date. This Friday, South Africa will become the ninth African country to introduce LEN. Read for updated resources to track this progress and ensure the field moves with speed, scale and equity.
A commentary by eight former US CDC directors urges the US Department of State to reform PEPFAR, not dismantle it; the growing Ebola outbreak and ongoing hantavirus concerns underscore the risks abrupt changes pose to global health security; and a proposed new US federal grant regulation could significantly expand political influence over scientific funding decisions and research priorities.
We are excited to release our first AI & HIV Newsletter! This new quarterly resource will provide advocates and the global community with the information and resources to engage with AI in ways that strengthen equity, protect individuals and communities and prioritize their inclusion, and ensure that technological innovation advances the HIV response rather than undermines it.
INTEREST 2026 took place from 12–15 May 2026, in Dar es Salaam, Tanzania. Read reflections and key takeaways from AVAC’s Grace Kumwenda and Access Bridge’s Wawira Nyagah.
showing 1-10 of 1231
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.